Open AccessEffect of brimonidine on patients undergoing uncontrolled IOP with beta‐blockers
Author(s) -
Taverniti L.,
Di Staso S.,
Arrico L.,
Giuffrè I.,
Recupero S. M.
Publication year - 2002
Publication title -
acta ophthalmologica scandinavica
Language(s) - English
Resource type - Journals
eISSN - 1600-0420
pISSN - 1395-3907
DOI - 10.1034/j.1600-0420.80.s236.33.x
Subject(s) - brimonidine , dorzolamide , medicine , discontinuation , ophthalmology , ocular hypertension , anesthesia , beta (programming language) , adverse effect , glaucoma , timolol , computer science , programming language
Summary The authors evaluated the effect of the replacement of β‐blockers with brimonidine drops in patients taking β‐blockers only or with dorzolamide, having IOP > 20 mmHg. The study was divided into two sections: one group treated with brimonidine b.i.d. (23 patients) and the other group treated with brimonidine + dorzolamide b.i.d. (17 patients). The effect of the substitution showed after 90 days of treatment with a reduction of 8.59 ± 1.2 mmHg ( P < 0.001) in the first group and 6.1 ± 1.7 mmHg ( P < 0.001) in the second group. Three patients in the first group and four patients in the second group presented minor adverse effects which did not justify discontinuation of treatment. Brimonidine was effective treatment as a substitute for β‐blockers only when associated with dorzolamide.